High Throughput Screening [HTS] Market Size to Hit US$ 69.46 Billion By 2032, With a Growing CAGR of 12.18% | Research by SNS Insider

A growing adoption of 3D cell cultures and organoids, which provide more physiologically relevant models for screening, enhancing the predictive accuracy of HTS assays.

1401 Lavaca ST 800, Austin Tx 78701


Pune, July 17, 2024 (GLOBE NEWSWIRE) -- High Throughput Screening [HTS] Market Size & Analysis:

“According to SNS Insider research, The High Throughput Screening Market size is valued at USD 25.80 Billion in 2023 and is anticipated to surpass USD 69.46 Billion by 2032, with a compound annual growth rate (CAGR) of 12.18% over the forecast period 2024-2032.”

Market growth is driven by factors such as the wide availability of open-access high-throughput screening laboratories, technological advancements in this field, and rapid development at research organizations.

Public availability of high-throughput screening (HTS) facilities has grown considerably over the last several years. From simple university screening centers to large molecular libraries and probe development network facilities. These facilities offer a comprehensive model of probe discovery in academia, using both standard and state-of-the-art assay technology for primary and secondary screening campaigns. This is one of the big pluses - knowledge sharing among scientists, researchers, etc.

The Columbia Genome Center, for example, provides state-of-the-art molecular screening services to investigators across the broad spectrum of research entities at the university. The European equivalent of the NIH program has also been established (EU-open-screen) and is open to all companies within Europe working on chemical biology. The motivation for the establishment of associations like high-throughput screening (HTS) centers is meant to boldly improve drug or target-related information or, more correctly said, processes in general. Therefore, open access gives an edge in knowledge transfer and can add value to the whole process, which could further increase the interest of end users in HTS technologies.


Get a Sample Report of High Throughput Screening [HTS] Market@ https://www.snsinsider.com/sample-request/4355

Major Players Analysis Listed in this Research Report are:

  • PerkinElmer Inc.
  • Bio-Rad Laboratories Inc.
  • Axxam SpA
  • Beckman Coulter Inc.
  • Merck KGaA
  • Tecan Group Ltd
  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • GE Healthcare
  • Danaher Corporation
  • Other Players

High Throughput Screening [HTS] Market Report Scope:

Report Attributes Details
Market Size in 2023  US$ 25.80 Bn
Market Size by 2032  US$ 69.46 Bn
CAGR  CAGR of 12.18% From 2024 to 2032
Base Year  2023
Forecast Period  2024-2032
Historical Data  2020-2022
Key Growth Factors •Increasing Usage of High Throughput Screening Solutions in Universities and Research Centers is responsible for Market Growth.
•The Open Access to High-throughput Screening Laboratories is Boosting the Market Growth.

Segmentation Dynamics

Reagents and kits dominated the market with a 45% share in 2023. This supremacy may be due to the versatility (can be used in different experiments), user-friendliness (pre-metered and prepared for purchase) as well as specificity (optimized accuracy). But we can see the growing instruments turning the tide. This has been driven by technological advancements allowing further features and embracing automation which can process samples quicker with a higher level of efficiency. It remains to be seen which segment will prove the most dominant in coming years, but both products are critical with instruments enabling high-end analysis and automation while reagents & kits remain a necessity for basic research as well as diagnostics.

Do you have any specific queries or need any customization research/data on High Throughput Screening [HTS] Market, Enquire Now@ https://www.snsinsider.com/enquiry/4355

High Throughput Screening [HTS] Market Key Segmentation:

By Technology

  • Ultra-high-throughput Screening
  • Cell-based Assays
  • Lab-on-a-chip
  • Label-free Technology

By Application

  • Target Identification
  • Primary Screening
  • Toxicology

By Products and Services

  • Instruments
  • Reagents, and Kits
  • Services

By End User

  • Pharmaceutical and Biotechnology Firms
  • Academia and Research Institutes
  • Contract Research Organizations

Regional Analysis

North America dominated the high-throughput screening market by 44% in 2023 mainly due to technological advancement within the U.S. With increasing pharmaceutical companies racing to be the first with a discovery of new drug molecules in 3D cell cultures has become even more popular.

Asia Pacific, on the other hand, is estimated to be growing at a higher CAGR during the forecast period due to increasing initiatives in new pharma molecules and their improved drug delivery standards. According to WHO, the countries with higher rates of growth in this region are Japan China; and India.

Regional Coverage

  • North America (US, Canada, Mexico)
  • Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe])
  • Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific)
  • Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East])
  • Africa [Nigeria, South Africa, Rest of Africa],
  • Latin America (Brazil, Argentina, Colombia Rest of Latin America)

Buy an Enterprise-User PDF of High Throughput Screening [HTS] Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/4355

Recent Developments

  • In 2024, Agilent Technologies Inc. announced a collaboration with Incyte, combining Agilent’s expertise and established track record in the development of companion diagnostics to assist Incyte in developing and commercializing its hematology with oncology portfolio. It permits Agilent to keep growing its companion diagnostics portfolio with disruptive biomarkers, and Incyte will be able to benefit from Agilent’s expertise. This covers IVD assay development, global regulatory approvals, and commercialization to assist clinical trials, as well as potential registration and commercialization of CDx in the United States and Europe.

Table of Contents – Major Key Points

1. Introduction

2. Industry Flowchart

3. Research Methodology

4. Market Dynamics

5. Porter’s 5 Forces Model

6. Pest Analysis

7. High Throughput Screening Market Segmentation, By Technology

8. High Throughput Screening Market Segmentation, By Application

9. High Throughput Screening Market Segmentation, By Products and Services

10. High Throughput Screening Market Segmentation, By End User

11. Regional Analysis

12. Company Profiles

13. Competitive Landscape

14. Use Case and Best Practices

15. Conclusion

Access Complete Report Details of High Throughput Screening Market Analysis & Outlook Study 2024-2032@ https://www.snsinsider.com/reports/high-throughput-screening-market-4355

[For more information or need any customization research mail us at info@snsinsider.com]

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

 

Contact Data